Response Prediction in Lung SBRT with Artificial Intelligence.

OBJECTIVE Lung cancer is the leading cause of cancer-related death worldwide. Although the majority of patients have locally advanced or metastatic disease at diagnosis, the incidence of early-stage non-small-cell lung cancer is expected to increase due to the wider use of thoracic CT scans. Primary...

Descripción completa

Detalles Bibliográficos
Publicado en:Turkish Journal of Oncology / Türk Onkoloji Dergisi Vol. 38; no. 3; pp. 288 - 295
Autores principales: ETIZ, Durmuş, YAKAR, Melek, AK, Güntülü, KÜTRI, Deniz, ÇELIK, Özer, METINTAŞ, Muzaffer
Formato: research tables/charts Journal Article
Publicado: KARE Publishing 2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=172259037&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 172259037
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        13007467
        B6JE
      jtl: Turkish Journal of Oncology / Türk Onkoloji Dergisi
      issn: 13007467
      maglogo: N
    pubinfo:
      dt: 2023
      vid: 38
      iid: 3
      pid: 62027
      pub: KARE Publishing
    artinfo:
      ui:
        172259037
        172259037
        172259037
        10.5505/tjo.2023.4008
        172259037
      ppf: 288
      ppct: 7
      formats:
      tig:
        atl: Response Prediction in Lung SBRT with Artificial Intelligence.
      aug:
        au:
          ETIZ, Durmuş
          YAKAR, Melek
          AK, Güntülü
          KÜTRI, Deniz
          ÇELIK, Özer
          METINTAŞ, Muzaffer
        affil: Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine, Eskişehir-Türkiye
      sug:
        subj:
          Artificial Intelligence Methods
          Radiosurgery
          Lung Neoplasms Mortality
          Neoplasm Recurrence, Local
          Neoplasm Staging
          Neoplasm Metastasis
          Human
          Male
          Female
          Logistic Regression
          Overall Survival
          Progression-Free Survival
          Confidence Intervals
          ROC Curve
          Sensitivity and Specificity
          Comparative Studies
          Tomography, X-Ray Computed
          Male
          Female
      ab: OBJECTIVE Lung cancer is the leading cause of cancer-related death worldwide. Although the majority of patients have locally advanced or metastatic disease at diagnosis, the incidence of early-stage non-small-cell lung cancer is expected to increase due to the wider use of thoracic CT scans. Primary tumor control and distant metastasis rates in early-stage lung cancer are similar for stereotactic body radiation therapy (SBRT) and surgery. Overall survival (OS) is lower for SBRT compared to surgery. Although some studies provide guidance on which cases will have a good response to SBRT, there is still no standard guideline. SBRT results are not the same in cases at the same stage or with the same metastatic burden. It is thought that there may be other parameters other than stage or tumor burden that affect the response. It is aimed to predict the response to SBRT with artificial intelligence in early-stage lung cancer, recurrent lung cancer, and lung metastases. METHODS Between September 2016 and April 2021, 137 cases and 148 lesions in which SBRT was applied by Eşkişehir Osmangazi University Faculty of Medicine Radiation Oncology Department were evaluated. To create a balanced data set, Synthetic Minority Oversampling Technique technique was used and 200 lesions were evaluated. Logistic Regression (LR), multilayer perceptron Classifier, Extreme Gradient Boosting, Support Vector Classifier, Random Forest Classifier, and Gaussian Naive Bayes algorithms were used. The data sets are divided into 85% training and 15% prediction sets. Models were created using the training set and validated using the prediction set. RESULTS Complete response was obtained in 41 tumors out of 148 tumors. The median OS after SBRT is 18 (2-61) months, and progression-free survival is 16 (0-61) months. Important variables are tumor diameter, NLR, presence of biopsy at diagnosis, tumor location and type, diagnosis, and histopathology. LR algorithm was determined as the best estimating algorithm with 80% accuracy (Confidence Interval, CI: 0.65-0.94, ROC AUC: 0.60), 66% sensitive and 90% specificity. CONCLUSION In order to use the current algorithm in clinical practice, it is necessary to increase the diversity of data and the number of patients by sharing data between centers.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N